A new drug that shrinks brain tumours in melanoma patients has had promising results in phase one trials.
Researchers say this drug could add months to the lives of patients whose melanoma has spread to the brain.
Up to this point, melanoma has been resistant to drug therapy. The next step is to test whether the findings are supported in larger cohorts of patients.
The research was funded by GlaxoSmithKline.
Read more at The University of Sydney